National Pension Service Purchases 426,697 Shares of Bristol Myers Squibb Company $BMY

Key Points

• National Pension Service increased its Bristol Myers Squibb stake by 8.4% in the fourth quarter, buying 426,697 shares and bringing its total holding to 5.53 million shares worth about $298.5 million.
• Bristol Myers Squibb beat first-quarter earnings and revenue estimates, reporting $1.58 EPS on $11.49 billion in revenue, and it maintained FY2026 guidance of 6.05–6.35 EPS.
• The company continues to pay a generous dividend, with a quarterly payout of $0.63 per share, equal to an annualized yield of about 4.4%.

National Pension Service grew its position in Bristol Myers Squibb Company (NYSE:BMY - Free Report) by 8.4% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 5,533,216 shares of the biopharmaceutical company's stock after acquiring an additional 426,697 shares during the period. National Pension Service owned about 0.27% of Bristol Myers Squibb worth $298,462,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Darwin Wealth Management LLC bought a new position in shares of Bristol Myers Squibb in the 2nd quarter valued at about $25,000. Physician Wealth Advisors Inc. grew its position in shares of Bristol Myers Squibb by 73.5% in the 4th quarter. Physician Wealth Advisors Inc. now owns 477 shares of the biopharmaceutical company's stock valued at $26,000 after acquiring an additional 202 shares during the period. EQ Wealth Advisors LLC bought a new position in shares of Bristol Myers Squibb in the 4th quarter valued at about $32,000. KERR FINANCIAL PLANNING Corp bought a new position in shares of Bristol Myers Squibb in the 3rd quarter valued at about $35,000. Finally, Garner Asset Management Corp bought a new position in shares of Bristol Myers Squibb in the 4th quarter valued at about $35,000. Institutional investors own 76.41% of the company's stock.

Bristol Myers Squibb Stock Performance

Shares of BMY stock opened at $56.93 on Friday. The company has a market capitalization of $116.26 billion, a price-to-earnings ratio of 15.99, a PEG ratio of 0.16 and a beta of 0.26. The company has a debt-to-equity ratio of 2.10, a quick ratio of 1.28 and a current ratio of 1.42. The company has a 50-day simple moving average of $58.36 and a 200 day simple moving average of $56.25. Bristol Myers Squibb Company has a 52 week low of $42.52 and a 52 week high of $62.89.

Bristol Myers Squibb (NYSE:BMY - Get Free Report) last announced its earnings results on Thursday, April 30th. The biopharmaceutical company reported $1.58 EPS for the quarter, topping the consensus estimate of $1.42 by $0.16. The business had revenue of $11.49 billion during the quarter, compared to the consensus estimate of $10.93 billion. Bristol Myers Squibb had a net margin of 15.01% and a return on equity of 64.87%. Bristol Myers Squibb's revenue was up 2.6% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $1.80 EPS. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. On average, sell-side analysts predict that Bristol Myers Squibb Company will post 6.31 earnings per share for the current year.

Bristol Myers Squibb Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Friday, May 1st. Shareholders of record on Thursday, April 2nd were issued a $0.63 dividend. The ex-dividend date of this dividend was Thursday, April 2nd. This represents a $2.52 dividend on an annualized basis and a yield of 4.4%. Bristol Myers Squibb's payout ratio is currently 70.79%.

Analyst Ratings Changes

A number of research analysts have recently commented on BMY shares. Weiss Ratings reissued a "hold (c)" rating on shares of Bristol Myers Squibb in a research report on Monday, March 23rd. Morgan Stanley reaffirmed an "underweight" rating and set a $40.00 target price on shares of Bristol Myers Squibb in a report on Friday, February 6th. Wall Street Zen raised shares of Bristol Myers Squibb from a "buy" rating to a "strong-buy" rating in a report on Sunday, April 19th. Cantor Fitzgerald lifted their target price on shares of Bristol Myers Squibb from $45.00 to $54.00 and gave the stock a "neutral" rating in a report on Wednesday, April 8th. Finally, Bank of America reduced their target price on shares of Bristol Myers Squibb from $68.00 to $67.00 and set a "buy" rating for the company in a report on Thursday, April 9th. Eight analysts have rated the stock with a Buy rating, ten have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, Bristol Myers Squibb currently has an average rating of "Hold" and an average target price of $61.31.

Insider Transactions at Bristol Myers Squibb

In other Bristol Myers Squibb news, EVP David V. Elkins sold 30,000 shares of the business's stock in a transaction dated Wednesday, April 1st. The shares were sold at an average price of $61.67, for a total value of $1,850,100.00. Following the completion of the sale, the executive vice president owned 159,248 shares of the company's stock, valued at $9,820,824.16. The trade was a 15.85% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. 0.05% of the stock is owned by corporate insiders.

About Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company's core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS's marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol Myers Squibb Company (NYSE:BMY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.